IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Open Date
Jun 5, 2026
Close Date
Jun 9, 2026
Min Investment
₹14,985
Lot Size
333 Shares
Issue Size
₹138.87 Cr
Price Range
₹42 - ₹42
Listing Date
Jun 12, 2026
Incorporated in the year 1993, Hexagon Nutrition Ltd. is a research-led nutrition company. The business is involved in the development and production of products in areas of micronutrient premixes, branded wellness and clinical nutrition, therapeutic formulations, and ready-to-use food products. It has three manufacturing units based in India located in Nasik (Maharashtra), Chennai (Tamil Nadu), and Thoothukudi (Tamil Nadu) and one more unit abroad in Tashkent, Uzbekistan. The two Indian units are located in Special Economic Zone areas in Chennai and Thoothukudi and offer benefits like easy access to port and duty-free imports. The product range can be segmented as follows: Products for branded wellness and clinical nutrition (B2C) Formulations of premix (B2B2C) ESG initiatives – Ready-to-Use Foods (RUFs) & Micronutrient Powders (MNPs) Hexagon Nutrition has a PAN-India omni-channel distribution system that includes retail pharmacies, hospital chains, online portals, e-pharmacy sites, and own branded sites like Pentasure, Obesigo, Pediagold, and Nutrone. It has over 358 distributors across India, including 8 multi-state distributors for domestic distribution. The firm has opened overseas branches in South Africa, Uzbekistan, and Hong Kong to facilitate its international operations. Its products have been sold to over 75 nations located in Asia, Africa, Europe, and South America during fiscal years 2023 to 2025. Hexagon Nutrition has two research & development centers located in Nasik and Chennai with the assistance of a team of 12 specialists. As of March 31, 2026, Hexagon had 527 employees.
Sotefin Bharat
| Companies Name | Open - Close | Issue Size | Min. Qty | Issue Price | Apply |
|---|---|---|---|---|---|
Sotefin Bharat SME | 16th Jul 2026 - 20th Jul 2026 | 89.76 Cr | 600 Shares | ₹ 178.00 | |
Caliber Mining & Logistics Mainboard | 17th Jul 2026 - 21st Jul 2026 | 450.00 Cr | 35 Shares | ₹ 402.00 |
IPO Doc
RHP PDFRevenue Growth
Company Valuation
Earning Expansion
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.
The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders. The company want to achieve the benefits of listing its shares on the stock exchanges.
The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders.
The company want to achieve the benefits of listing its shares on the stock exchanges.
Times subscribed by category (bars capped at 10x for readability). Dashed line marks 1.0x (fully subscribed).
In Cr.
Hexagon Nutrition
404 Global Chamber, Adarsh Nagar Link Road, Andheri (W), Mumbai, Maharashtra - 400053.
The company’s growth is driven by innovation, having two research and development centres, 12 specialists working on innovation, 11 products launched in the past 3+ years, and 9 products currently in the pipeline, with stable investment in R&D at 0.68–0.91% during FY23-FY25.
The company has faced operational disruptions due to quality issues. In July 2023, a Salmonella contamination incident led to the shutdown of the Thoothukudi facility for ~6 to 7 months, which resulted in a direct cost of ~₹6.57 crore along with an additional burden of ~₹1.51 crore. Further, during FY26, a selenium content-related issue at the Chennai facility led to rejection of batches and caused losses of ~₹4.23 crore.
The company's raw material cost has seen a rise over the last few periods, up from 46.44% of revenue in FY24 to 47.65% in FY25 and further to 60.71% in 9MFY26. The procurement base also remains concentrated, with the top 10 suppliers contributing 53.15% of total purchases. In addition, it continues to rely on imports from China, which formed 58.38% of total imports. This exposes the business to risks related to supply chain disruptions, fluctuations in raw material prices and geopolitical developments.
The operating cash flow became negative at ₹(4.07) crore during 9MFY26 due to the increase in the working capital cycle days up to 149 days, receivables stood at ₹84.95 crore, while short-term borrowings increased almost double to ₹29.13 crore, showing rising liquidity and funding pressure.